abstract: UNASSIGNED: 6522 Background: Approximately half of @entity5 @entity0 do not respond to alemtuzumab and others progress after responding to alemtuzumab. We report here factors predictive for lack of response and approaches to achieve the best outcome for these @entity0 . METHODS: 91 @entity0 with relapsed or @entity5 received alemtuzumab aiming for @entity1 ( @entity1 ) negativity. Factors correlated with response were reviewed and strategies for overcoming resistance or relapse are reported. RESULTS: The chance of response was associated with lymph node size (p <0.0001): [Figure: see text] High dose @entity2 (HDMP; 1g/m(2)/day x5 every 4 weeks; 4 @entity0 ) or @entity4 (1) were used to reduce bulky nodes prior to alemtuzumab. 2 of 5 had a resolution of lymph nodes with both achieving @entity1 negative remissions with alemtuzumab. The other 3 did not respond to HDMP or alemtuzumab. 8 @entity0 refractory to alemtuzumab, due to bulky lymph nodes, received alemtuzumab with concurrent @entity3 and 6 responded (2 @entity1 negative, 2 CR, 2 PR). In addition, 9 @entity0 relapsing after a median of 23 months (range 8-46) from alemtuzumab were retreated of which 5 responded (1 @entity1 negative, 2 CR, 2 PR): 2 of the non-responders then received alemtuzumab combined with @entity3 with 1 achieving @entity1 negativity. One @entity0 was treated on relapse directly with the alemtuzumab/ @entity3 combination and achieved a @entity1 negative CR. Thus 11 refractory @entity0 received combined alemtuzumab and @entity3 with 8 responding (4 @entity1 negative, 2 CR, 2 PR). CONCLUSIONS: Gross lymphadenopathy predicts for poor response to alemtuzumab but therapy with HDMP or @entity4 followed by alemtuzumab can be effective in achieving @entity1 negative CR. The majority of alemtuzumab refractory @entity0 (8/11) respond to the addition of @entity3 . Retreatment with alemtuzumab was effective for 3 of 7 relapsing @entity0 . [Table: see text].

title: Optimising alemtuzumab therapy for refractory B cell @entity5 ( XXXX ).

answer: @entity5


abstract: UNASSIGNED: 6522 Background: Approximately half of @entity5 @entity0 do not respond to alemtuzumab and others progress after responding to alemtuzumab. We report here factors predictive for lack of response and approaches to achieve the best outcome for these @entity0 . METHODS: 91 @entity0 with relapsed or @entity5 received alemtuzumab aiming for @entity1 ( @entity1 ) negativity. Factors correlated with response were reviewed and strategies for overcoming resistance or relapse are reported. RESULTS: The chance of response was associated with lymph node size (p <0.0001): [Figure: see text] High dose @entity2 (HDMP; 1g/m(2)/day x5 every 4 weeks; 4 @entity0 ) or @entity4 (1) were used to reduce bulky nodes prior to alemtuzumab. 2 of 5 had a resolution of lymph nodes with both achieving @entity1 negative remissions with alemtuzumab. The other 3 did not respond to HDMP or alemtuzumab. 8 @entity0 refractory to alemtuzumab, due to bulky lymph nodes, received alemtuzumab with concurrent @entity3 and 6 responded (2 @entity1 negative, 2 CR, 2 PR). In addition, 9 @entity0 relapsing after a median of 23 months (range 8-46) from alemtuzumab were retreated of which 5 responded (1 @entity1 negative, 2 CR, 2 PR): 2 of the non-responders then received alemtuzumab combined with @entity3 with 1 achieving @entity1 negativity. One @entity0 was treated on relapse directly with the alemtuzumab/ @entity3 combination and achieved a @entity1 negative CR. Thus 11 refractory @entity0 received combined alemtuzumab and @entity3 with 8 responding (4 @entity1 negative, 2 CR, 2 PR). CONCLUSIONS: Gross lymphadenopathy predicts for poor response to alemtuzumab but therapy with HDMP or @entity4 followed by alemtuzumab can be effective in achieving @entity1 negative CR. The majority of alemtuzumab refractory @entity0 (8/11) respond to the addition of @entity3 . Retreatment with alemtuzumab was effective for 3 of 7 relapsing @entity0 . [Table: see text].

title: Optimising alemtuzumab therapy for refractory B cell XXXX ( @entity5 ).

answer: @entity5


abstract: During a five-year period, 104 @entity0 underwent a pericardial window procedure to diagnose possible @entity2 . Eighty-eight procedures were performed by a subxiphoid approach, and 16 were transdiaphragmatic in combination with an exploratory laparotomy. There were 51 @entity0 with stab wounds, 45 with gunshot wounds, and eight with @entity1 . All penetrating wounds were near the heart. In seven @entity0 the window disclosed @entity2 with no clinical signs of tamponade or shock. Fifty-one @entity0 had signs of tamponade; however, only 12 of them had a @entity2 diagnosed by pericardial window. Nineteen @entity0 had @entity2 . One examination had false-negative results and one study had false-positive results. @entity2 repaired included the right ventricle (eight), left ventricle (three), right atrium (five), and @entity2 (three). Complications were negligible and consisted of minor wound infections (two) and @entity4 (two). The pericardial window provides a rapid and safe means of diagnosing @entity2 in @entity0 with equivocal signs of @entity3 while sparing the @entity0 without a heart wound a major operation.

title: Diagnostic pericardial window. A safe alternative to exploratory thoracotomy for suspected XXXX .

answer: @entity3


abstract: UNASSIGNED: 4715 Background: In locally advanced @entity8 of @entity11 radiation therapy, either alone, or in combination with chemotherapy is the treatment of choice for @entity0 whose disease is not amenable to surgery. This study was carried out to evaluate the efficacy and @entity6 of Neoadjuvant chemotherapy with @entity5 and @entity13 followed by concurrent chemoradiotherapy in locally advanced @entity7 . @entity0 AND METHODS: 22 @entity0 were enrolled. All @entity0 initially received 4 cycles of @entity5 and @entity13 , after which response evaluation was done with CT scanning and ultrasonography. @entity0 with complete response (CR) and partial response (PR) received 2 more cycles followed by radical radiotherapy with weekly @entity5 as radiation sensitizer. Those who had @entity2 ( @entity2 ) or @entity3 ( @entity3 ) were given concurrent chemoradiotherapy after four cycles. RESULTS: Twenty @entity0 were males and two were females. The median age was 52 years (range 35-70 years). All @entity0 had histopathological @entity12 . Eleven (50%) @entity0 had T3 lesion, 7(31.81%) had T4 and 4(18.18%) cases had @entity4 . Out of 22, 6(27.27%) @entity0 showed CR, and PR was seen in 9(40.90%) @entity0 . Four (18.18%) @entity0 had @entity2 whereas 3 @entity0 showed progression of the disease. Two cases out of four having @entity2 showed regression of @entity1 after concurrent chemoradiotherapy. No grade III/IV @entity6 was seen. Common @entity6 observed were Neutrogena, fatigue, @entity10 and @entity9 . CONCLUSION: Neoadjuvant chemotherapy with @entity5 - @entity13 followed by concurrent chemoradiotherapy is a well tolerable and effective treatment modality to achieve significant @entity1 response in locally advanced @entity7 . No significant financial relationships to disclose.

title: Neoadjuvant chemotherapy with @entity5 and XXXX followed by concurrent chemoradiotherapy in locally advanced @entity8 of @entity11 .

answer: @entity13


abstract: UNASSIGNED: 4715 Background: In locally advanced @entity8 of @entity11 radiation therapy, either alone, or in combination with chemotherapy is the treatment of choice for @entity0 whose disease is not amenable to surgery. This study was carried out to evaluate the efficacy and @entity6 of Neoadjuvant chemotherapy with @entity5 and @entity13 followed by concurrent chemoradiotherapy in locally advanced @entity7 . @entity0 AND METHODS: 22 @entity0 were enrolled. All @entity0 initially received 4 cycles of @entity5 and @entity13 , after which response evaluation was done with CT scanning and ultrasonography. @entity0 with complete response (CR) and partial response (PR) received 2 more cycles followed by radical radiotherapy with weekly @entity5 as radiation sensitizer. Those who had @entity2 ( @entity2 ) or @entity3 ( @entity3 ) were given concurrent chemoradiotherapy after four cycles. RESULTS: Twenty @entity0 were males and two were females. The median age was 52 years (range 35-70 years). All @entity0 had histopathological @entity12 . Eleven (50%) @entity0 had T3 lesion, 7(31.81%) had T4 and 4(18.18%) cases had @entity4 . Out of 22, 6(27.27%) @entity0 showed CR, and PR was seen in 9(40.90%) @entity0 . Four (18.18%) @entity0 had @entity2 whereas 3 @entity0 showed progression of the disease. Two cases out of four having @entity2 showed regression of @entity1 after concurrent chemoradiotherapy. No grade III/IV @entity6 was seen. Common @entity6 observed were Neutrogena, fatigue, @entity10 and @entity9 . CONCLUSION: Neoadjuvant chemotherapy with @entity5 - @entity13 followed by concurrent chemoradiotherapy is a well tolerable and effective treatment modality to achieve significant @entity1 response in locally advanced @entity7 . No significant financial relationships to disclose.

title: Neoadjuvant chemotherapy with @entity5 and @entity13 followed by concurrent chemoradiotherapy in locally advanced XXXX of @entity11 .

answer: @entity8


abstract: UNASSIGNED: 4715 Background: In locally advanced @entity8 of @entity11 radiation therapy, either alone, or in combination with chemotherapy is the treatment of choice for @entity0 whose disease is not amenable to surgery. This study was carried out to evaluate the efficacy and @entity6 of Neoadjuvant chemotherapy with @entity5 and @entity13 followed by concurrent chemoradiotherapy in locally advanced @entity7 . @entity0 AND METHODS: 22 @entity0 were enrolled. All @entity0 initially received 4 cycles of @entity5 and @entity13 , after which response evaluation was done with CT scanning and ultrasonography. @entity0 with complete response (CR) and partial response (PR) received 2 more cycles followed by radical radiotherapy with weekly @entity5 as radiation sensitizer. Those who had @entity2 ( @entity2 ) or @entity3 ( @entity3 ) were given concurrent chemoradiotherapy after four cycles. RESULTS: Twenty @entity0 were males and two were females. The median age was 52 years (range 35-70 years). All @entity0 had histopathological @entity12 . Eleven (50%) @entity0 had T3 lesion, 7(31.81%) had T4 and 4(18.18%) cases had @entity4 . Out of 22, 6(27.27%) @entity0 showed CR, and PR was seen in 9(40.90%) @entity0 . Four (18.18%) @entity0 had @entity2 whereas 3 @entity0 showed progression of the disease. Two cases out of four having @entity2 showed regression of @entity1 after concurrent chemoradiotherapy. No grade III/IV @entity6 was seen. Common @entity6 observed were Neutrogena, fatigue, @entity10 and @entity9 . CONCLUSION: Neoadjuvant chemotherapy with @entity5 - @entity13 followed by concurrent chemoradiotherapy is a well tolerable and effective treatment modality to achieve significant @entity1 response in locally advanced @entity7 . No significant financial relationships to disclose.

title: Neoadjuvant chemotherapy with @entity5 and @entity13 followed by concurrent chemoradiotherapy in locally advanced @entity8 of XXXX .

answer: @entity11


abstract: UNASSIGNED: 4715 Background: In locally advanced @entity8 of @entity11 radiation therapy, either alone, or in combination with chemotherapy is the treatment of choice for @entity0 whose disease is not amenable to surgery. This study was carried out to evaluate the efficacy and @entity6 of Neoadjuvant chemotherapy with @entity5 and @entity13 followed by concurrent chemoradiotherapy in locally advanced @entity7 . @entity0 AND METHODS: 22 @entity0 were enrolled. All @entity0 initially received 4 cycles of @entity5 and @entity13 , after which response evaluation was done with CT scanning and ultrasonography. @entity0 with complete response (CR) and partial response (PR) received 2 more cycles followed by radical radiotherapy with weekly @entity5 as radiation sensitizer. Those who had @entity2 ( @entity2 ) or @entity3 ( @entity3 ) were given concurrent chemoradiotherapy after four cycles. RESULTS: Twenty @entity0 were males and two were females. The median age was 52 years (range 35-70 years). All @entity0 had histopathological @entity12 . Eleven (50%) @entity0 had T3 lesion, 7(31.81%) had T4 and 4(18.18%) cases had @entity4 . Out of 22, 6(27.27%) @entity0 showed CR, and PR was seen in 9(40.90%) @entity0 . Four (18.18%) @entity0 had @entity2 whereas 3 @entity0 showed progression of the disease. Two cases out of four having @entity2 showed regression of @entity1 after concurrent chemoradiotherapy. No grade III/IV @entity6 was seen. Common @entity6 observed were Neutrogena, fatigue, @entity10 and @entity9 . CONCLUSION: Neoadjuvant chemotherapy with @entity5 - @entity13 followed by concurrent chemoradiotherapy is a well tolerable and effective treatment modality to achieve significant @entity1 response in locally advanced @entity7 . No significant financial relationships to disclose.

title: Neoadjuvant chemotherapy with XXXX and @entity13 followed by concurrent chemoradiotherapy in locally advanced @entity8 of @entity11 .

answer: @entity5


abstract: UNASSIGNED: 668 Background: In Western populations, @entity11 ( @entity13 ) has been proven effective for the prevention of @entity7 ( @entity7 ) from bone metastases. For @entity0 @entity1 , @entity13 was shown to be superior to pamidronate. However, the efficacy of @entity13 is unknown in Japanese @entity1 . We report here data from the first randomized, placebo-controlled study of @entity13 in Japanese @entity1 . METHODS: Japanese @entity1 with bone metastases from @entity0 were randomized to either @entity13 4mg i.v. infusion over 15 min every 4 weeks or placebo (P). The primary efficacy endpoint was SRE rate ratio (ratio of number of @entity7 per year for @entity13 -treated @entity1 over that for placebo) at 1 year. @entity7 included pathologic @entity3 , @entity9 , and surgery to treat or prevent @entity3 . Secondary endpoints included proportion of @entity1 with >= 1 SRE, time to first SRE and multiple event analysis (MEA: A-G model). @entity2 induced @entity10 was included in the SRE composite in secondary endpoints. Safety was assessed according to NCI-CTC. RESULTS: 227 @entity1 (median age 53 years) were accrued to the study with 114 in the @entity13 arm and 113 in the P arm. @entity1 were well matched with regard to baseline clinical characteristics. The primary endpoint, SRE rate ratio was 0.61 (p=0.027), indicating that SRE rate was reduced by 39% with @entity13 . Proportions of @entity1 with >= 1 SRE were 30.7% and 52.2% for the @entity13 and P group, respectively (p=0.001). Median time to first SRE were 360 days in the P group while it did not reach in the @entity13 group (p=0.004). Risk ratio of @entity13 to P was 0.56 by MEA (p=0.009). @entity13 was well tolerated. The most common adverse effects observed more frequently in the @entity13 vs. P group were @entity4 (55% vs. 33%), @entity8 (44.5% vs. 31.9%) and @entity12 (21.1% vs. 15.9%). One @entity1 in the @entity13 group (0.9%) experienced increased serum @entity6 . CONCLUSIONS: @entity13 4mg demonstrated significant clinical efficacy in Japanese @entity1 for preventing @entity5 with bone metastases, with an overall 44% reduction in the risk of experiencing @entity7 as shown by MEA. [Table: see text].

title: A randomized, double-blind, placebo-controlled phase III trial of @entity11 in the prevention of XXXX in Japanese @entity1 with bone metastases from @entity0 .

answer: @entity5


abstract: UNASSIGNED: 668 Background: In Western populations, @entity11 ( @entity13 ) has been proven effective for the prevention of @entity7 ( @entity7 ) from bone metastases. For @entity0 @entity1 , @entity13 was shown to be superior to pamidronate. However, the efficacy of @entity13 is unknown in Japanese @entity1 . We report here data from the first randomized, placebo-controlled study of @entity13 in Japanese @entity1 . METHODS: Japanese @entity1 with bone metastases from @entity0 were randomized to either @entity13 4mg i.v. infusion over 15 min every 4 weeks or placebo (P). The primary efficacy endpoint was SRE rate ratio (ratio of number of @entity7 per year for @entity13 -treated @entity1 over that for placebo) at 1 year. @entity7 included pathologic @entity3 , @entity9 , and surgery to treat or prevent @entity3 . Secondary endpoints included proportion of @entity1 with >= 1 SRE, time to first SRE and multiple event analysis (MEA: A-G model). @entity2 induced @entity10 was included in the SRE composite in secondary endpoints. Safety was assessed according to NCI-CTC. RESULTS: 227 @entity1 (median age 53 years) were accrued to the study with 114 in the @entity13 arm and 113 in the P arm. @entity1 were well matched with regard to baseline clinical characteristics. The primary endpoint, SRE rate ratio was 0.61 (p=0.027), indicating that SRE rate was reduced by 39% with @entity13 . Proportions of @entity1 with >= 1 SRE were 30.7% and 52.2% for the @entity13 and P group, respectively (p=0.001). Median time to first SRE were 360 days in the P group while it did not reach in the @entity13 group (p=0.004). Risk ratio of @entity13 to P was 0.56 by MEA (p=0.009). @entity13 was well tolerated. The most common adverse effects observed more frequently in the @entity13 vs. P group were @entity4 (55% vs. 33%), @entity8 (44.5% vs. 31.9%) and @entity12 (21.1% vs. 15.9%). One @entity1 in the @entity13 group (0.9%) experienced increased serum @entity6 . CONCLUSIONS: @entity13 4mg demonstrated significant clinical efficacy in Japanese @entity1 for preventing @entity5 with bone metastases, with an overall 44% reduction in the risk of experiencing @entity7 as shown by MEA. [Table: see text].

title: A randomized, double-blind, placebo-controlled phase III trial of @entity11 in the prevention of @entity5 in Japanese @entity1 with bone metastases from XXXX .

answer: @entity0


abstract: UNASSIGNED: 668 Background: In Western populations, @entity11 ( @entity13 ) has been proven effective for the prevention of @entity7 ( @entity7 ) from bone metastases. For @entity0 @entity1 , @entity13 was shown to be superior to pamidronate. However, the efficacy of @entity13 is unknown in Japanese @entity1 . We report here data from the first randomized, placebo-controlled study of @entity13 in Japanese @entity1 . METHODS: Japanese @entity1 with bone metastases from @entity0 were randomized to either @entity13 4mg i.v. infusion over 15 min every 4 weeks or placebo (P). The primary efficacy endpoint was SRE rate ratio (ratio of number of @entity7 per year for @entity13 -treated @entity1 over that for placebo) at 1 year. @entity7 included pathologic @entity3 , @entity9 , and surgery to treat or prevent @entity3 . Secondary endpoints included proportion of @entity1 with >= 1 SRE, time to first SRE and multiple event analysis (MEA: A-G model). @entity2 induced @entity10 was included in the SRE composite in secondary endpoints. Safety was assessed according to NCI-CTC. RESULTS: 227 @entity1 (median age 53 years) were accrued to the study with 114 in the @entity13 arm and 113 in the P arm. @entity1 were well matched with regard to baseline clinical characteristics. The primary endpoint, SRE rate ratio was 0.61 (p=0.027), indicating that SRE rate was reduced by 39% with @entity13 . Proportions of @entity1 with >= 1 SRE were 30.7% and 52.2% for the @entity13 and P group, respectively (p=0.001). Median time to first SRE were 360 days in the P group while it did not reach in the @entity13 group (p=0.004). Risk ratio of @entity13 to P was 0.56 by MEA (p=0.009). @entity13 was well tolerated. The most common adverse effects observed more frequently in the @entity13 vs. P group were @entity4 (55% vs. 33%), @entity8 (44.5% vs. 31.9%) and @entity12 (21.1% vs. 15.9%). One @entity1 in the @entity13 group (0.9%) experienced increased serum @entity6 . CONCLUSIONS: @entity13 4mg demonstrated significant clinical efficacy in Japanese @entity1 for preventing @entity5 with bone metastases, with an overall 44% reduction in the risk of experiencing @entity7 as shown by MEA. [Table: see text].

title: A randomized, double-blind, placebo-controlled phase III trial of XXXX in the prevention of @entity5 in Japanese @entity1 with bone metastases from @entity0 .

answer: @entity11


abstract: UNASSIGNED: 668 Background: In Western populations, @entity11 ( @entity13 ) has been proven effective for the prevention of @entity7 ( @entity7 ) from bone metastases. For @entity0 @entity1 , @entity13 was shown to be superior to pamidronate. However, the efficacy of @entity13 is unknown in Japanese @entity1 . We report here data from the first randomized, placebo-controlled study of @entity13 in Japanese @entity1 . METHODS: Japanese @entity1 with bone metastases from @entity0 were randomized to either @entity13 4mg i.v. infusion over 15 min every 4 weeks or placebo (P). The primary efficacy endpoint was SRE rate ratio (ratio of number of @entity7 per year for @entity13 -treated @entity1 over that for placebo) at 1 year. @entity7 included pathologic @entity3 , @entity9 , and surgery to treat or prevent @entity3 . Secondary endpoints included proportion of @entity1 with >= 1 SRE, time to first SRE and multiple event analysis (MEA: A-G model). @entity2 induced @entity10 was included in the SRE composite in secondary endpoints. Safety was assessed according to NCI-CTC. RESULTS: 227 @entity1 (median age 53 years) were accrued to the study with 114 in the @entity13 arm and 113 in the P arm. @entity1 were well matched with regard to baseline clinical characteristics. The primary endpoint, SRE rate ratio was 0.61 (p=0.027), indicating that SRE rate was reduced by 39% with @entity13 . Proportions of @entity1 with >= 1 SRE were 30.7% and 52.2% for the @entity13 and P group, respectively (p=0.001). Median time to first SRE were 360 days in the P group while it did not reach in the @entity13 group (p=0.004). Risk ratio of @entity13 to P was 0.56 by MEA (p=0.009). @entity13 was well tolerated. The most common adverse effects observed more frequently in the @entity13 vs. P group were @entity4 (55% vs. 33%), @entity8 (44.5% vs. 31.9%) and @entity12 (21.1% vs. 15.9%). One @entity1 in the @entity13 group (0.9%) experienced increased serum @entity6 . CONCLUSIONS: @entity13 4mg demonstrated significant clinical efficacy in Japanese @entity1 for preventing @entity5 with bone metastases, with an overall 44% reduction in the risk of experiencing @entity7 as shown by MEA. [Table: see text].

title: A randomized, double-blind, placebo-controlled phase III trial of @entity11 in the prevention of @entity5 in Japanese XXXX with bone metastases from @entity0 .

answer: @entity1


abstract: UNASSIGNED: 2123 @entity1 ( @entity1 ) consists of a heterogeneous group of @entity1 that have acquired the capacity to metastasize before the development of a clinically evident @entity3 . They represent about 5-10% of all @entity1 . This study was designed to evaluate the efficacy and @entity5 of @entity12 / @entity10 combination chemotherapy in @entity0 with @entity1 . The rationale for choosing this combination is based on available clinical data that @entity12 and @entity10 have shown considerable clinical activity in various common @entity1 including lung, breast, stomach, esophagus, @entity4 . From January 2001 to September 2003, 37 @entity0 with @entity1 received 21-day cycles of @entity12 175 mg/m(2) i.v. and @entity10 60 mg/m(2) i.v. on day 1. 31 @entity0 had @entity8 subtypes. The @entity0 received a total of 138 cycles of chemotherapy. The median number of cycles of chemotherapy per @entity0 was 4. The median age of the @entity0 was 53 (range, 21-71) years. The male to female ratio was 1:2.1. Initial presentations were @entity15 , @entity6 , @entity7 , pelvic mass, metastatic @entity14 and @entity11 . Of these @entity0 , 36 @entity0 were evaluable for efficacy and @entity5 . Of the evaluable and measurable 26 @entity0 , complete response was in 1 @entity0 , and partial response was in 10 @entity0 . The overall response rate was 42% (95% C.I., 23-61%). Stable disease was seen in 6 @entity0 , progressive disease in 9 @entity0 . Median time to progression was 4 (95% C.I., 1.3-6.8) months. Median overall survival was 11 (95% C.I., 8.3-13.5) months. No prognostic factor was identified in univariate analysis. However, @entity0 with good performance status and @entity0 with normal @entity9 level showed marginal progression-free survival benefits (good PS vs poor PS; 5.2 vs 2.7 months, p=0.065) (normal @entity9 vs abnormal @entity9 ; 5.2 vs 1.9 months, p=0.066). The major @entity5 were @entity2 and @entity13 . Grade 4 @entity13 occurred in 10 cases, but febrile @entity13 was seen in 4 cases. Our data suggests that this @entity12 / @entity10 combination regimen is well tolerated with an encouraging level of activity for @entity0 with @entity1 . No significant financial relationships to disclose.

title: @entity12 plus XXXX in @entity1 of unknown primary site ( @entity1 ).

answer: @entity10


abstract: UNASSIGNED: 2123 @entity1 ( @entity1 ) consists of a heterogeneous group of @entity1 that have acquired the capacity to metastasize before the development of a clinically evident @entity3 . They represent about 5-10% of all @entity1 . This study was designed to evaluate the efficacy and @entity5 of @entity12 / @entity10 combination chemotherapy in @entity0 with @entity1 . The rationale for choosing this combination is based on available clinical data that @entity12 and @entity10 have shown considerable clinical activity in various common @entity1 including lung, breast, stomach, esophagus, @entity4 . From January 2001 to September 2003, 37 @entity0 with @entity1 received 21-day cycles of @entity12 175 mg/m(2) i.v. and @entity10 60 mg/m(2) i.v. on day 1. 31 @entity0 had @entity8 subtypes. The @entity0 received a total of 138 cycles of chemotherapy. The median number of cycles of chemotherapy per @entity0 was 4. The median age of the @entity0 was 53 (range, 21-71) years. The male to female ratio was 1:2.1. Initial presentations were @entity15 , @entity6 , @entity7 , pelvic mass, metastatic @entity14 and @entity11 . Of these @entity0 , 36 @entity0 were evaluable for efficacy and @entity5 . Of the evaluable and measurable 26 @entity0 , complete response was in 1 @entity0 , and partial response was in 10 @entity0 . The overall response rate was 42% (95% C.I., 23-61%). Stable disease was seen in 6 @entity0 , progressive disease in 9 @entity0 . Median time to progression was 4 (95% C.I., 1.3-6.8) months. Median overall survival was 11 (95% C.I., 8.3-13.5) months. No prognostic factor was identified in univariate analysis. However, @entity0 with good performance status and @entity0 with normal @entity9 level showed marginal progression-free survival benefits (good PS vs poor PS; 5.2 vs 2.7 months, p=0.065) (normal @entity9 vs abnormal @entity9 ; 5.2 vs 1.9 months, p=0.066). The major @entity5 were @entity2 and @entity13 . Grade 4 @entity13 occurred in 10 cases, but febrile @entity13 was seen in 4 cases. Our data suggests that this @entity12 / @entity10 combination regimen is well tolerated with an encouraging level of activity for @entity0 with @entity1 . No significant financial relationships to disclose.

title: @entity12 plus @entity10 in XXXX of unknown primary site ( @entity1 ).

answer: @entity1


abstract: UNASSIGNED: 2123 @entity1 ( @entity1 ) consists of a heterogeneous group of @entity1 that have acquired the capacity to metastasize before the development of a clinically evident @entity3 . They represent about 5-10% of all @entity1 . This study was designed to evaluate the efficacy and @entity5 of @entity12 / @entity10 combination chemotherapy in @entity0 with @entity1 . The rationale for choosing this combination is based on available clinical data that @entity12 and @entity10 have shown considerable clinical activity in various common @entity1 including lung, breast, stomach, esophagus, @entity4 . From January 2001 to September 2003, 37 @entity0 with @entity1 received 21-day cycles of @entity12 175 mg/m(2) i.v. and @entity10 60 mg/m(2) i.v. on day 1. 31 @entity0 had @entity8 subtypes. The @entity0 received a total of 138 cycles of chemotherapy. The median number of cycles of chemotherapy per @entity0 was 4. The median age of the @entity0 was 53 (range, 21-71) years. The male to female ratio was 1:2.1. Initial presentations were @entity15 , @entity6 , @entity7 , pelvic mass, metastatic @entity14 and @entity11 . Of these @entity0 , 36 @entity0 were evaluable for efficacy and @entity5 . Of the evaluable and measurable 26 @entity0 , complete response was in 1 @entity0 , and partial response was in 10 @entity0 . The overall response rate was 42% (95% C.I., 23-61%). Stable disease was seen in 6 @entity0 , progressive disease in 9 @entity0 . Median time to progression was 4 (95% C.I., 1.3-6.8) months. Median overall survival was 11 (95% C.I., 8.3-13.5) months. No prognostic factor was identified in univariate analysis. However, @entity0 with good performance status and @entity0 with normal @entity9 level showed marginal progression-free survival benefits (good PS vs poor PS; 5.2 vs 2.7 months, p=0.065) (normal @entity9 vs abnormal @entity9 ; 5.2 vs 1.9 months, p=0.066). The major @entity5 were @entity2 and @entity13 . Grade 4 @entity13 occurred in 10 cases, but febrile @entity13 was seen in 4 cases. Our data suggests that this @entity12 / @entity10 combination regimen is well tolerated with an encouraging level of activity for @entity0 with @entity1 . No significant financial relationships to disclose.

title: @entity12 plus @entity10 in @entity1 of unknown primary site ( XXXX ).

answer: @entity1


abstract: UNASSIGNED: 2123 @entity1 ( @entity1 ) consists of a heterogeneous group of @entity1 that have acquired the capacity to metastasize before the development of a clinically evident @entity3 . They represent about 5-10% of all @entity1 . This study was designed to evaluate the efficacy and @entity5 of @entity12 / @entity10 combination chemotherapy in @entity0 with @entity1 . The rationale for choosing this combination is based on available clinical data that @entity12 and @entity10 have shown considerable clinical activity in various common @entity1 including lung, breast, stomach, esophagus, @entity4 . From January 2001 to September 2003, 37 @entity0 with @entity1 received 21-day cycles of @entity12 175 mg/m(2) i.v. and @entity10 60 mg/m(2) i.v. on day 1. 31 @entity0 had @entity8 subtypes. The @entity0 received a total of 138 cycles of chemotherapy. The median number of cycles of chemotherapy per @entity0 was 4. The median age of the @entity0 was 53 (range, 21-71) years. The male to female ratio was 1:2.1. Initial presentations were @entity15 , @entity6 , @entity7 , pelvic mass, metastatic @entity14 and @entity11 . Of these @entity0 , 36 @entity0 were evaluable for efficacy and @entity5 . Of the evaluable and measurable 26 @entity0 , complete response was in 1 @entity0 , and partial response was in 10 @entity0 . The overall response rate was 42% (95% C.I., 23-61%). Stable disease was seen in 6 @entity0 , progressive disease in 9 @entity0 . Median time to progression was 4 (95% C.I., 1.3-6.8) months. Median overall survival was 11 (95% C.I., 8.3-13.5) months. No prognostic factor was identified in univariate analysis. However, @entity0 with good performance status and @entity0 with normal @entity9 level showed marginal progression-free survival benefits (good PS vs poor PS; 5.2 vs 2.7 months, p=0.065) (normal @entity9 vs abnormal @entity9 ; 5.2 vs 1.9 months, p=0.066). The major @entity5 were @entity2 and @entity13 . Grade 4 @entity13 occurred in 10 cases, but febrile @entity13 was seen in 4 cases. Our data suggests that this @entity12 / @entity10 combination regimen is well tolerated with an encouraging level of activity for @entity0 with @entity1 . No significant financial relationships to disclose.

title: XXXX plus @entity10 in @entity1 of unknown primary site ( @entity1 ).

answer: @entity12


abstract: UNASSIGNED: 654 Background: At the time of diagnosis, early stages of @entity0 already have microscopic @entity1 in the bone marrow. These @entity1 are resistant to adjuvant chemotherapy. The mechanisms of this resistance are not understood. In a model we developed, @entity4 ( @entity4 ), present in large deposits in the bone @entity3 , inhibits proliferation of well-differentiated @entity0 cells and induces a state of dormancy. In turn, @entity4 also induces an increased expression of integrins a5 and b1. Through these integrins, the cells bind @entity8 and activate survival signaling through the PI3 kinase/ @entity5 pathway. Disruption of this signaling may induce cell death in the dormant cells or render them susceptible to cytotoxic therapy. @entity7 , that have reported activity against @entity2 cells, have been shown to modulate @entity5 phosphorylation. METHODS: We investigated the role of all @entity6 (ATRA) in inhibiting @entity5 activation in dormant clones and their survival. Two well-differentiated @entity0 cell lines, MCF-7 and T-47D were used in the studies. Cells were incubated with @entity4 10 ng/ml in @entity8 -coated tissue culture plates at clonogenic densities and ATRA was added at variable concentrations after three days in culture for an additional three or six days. Colonies of 2-10 cells (dormant clones) were counted and lysates were analyzed by Western blot. RESULTS: @entity4 upregulated the expression of integrins a5 and b1 on Western blots after three and six days and increased the phosphorylation of @entity5 and its downstream target @entity9 /beta. Incubation of the dormant cells with ATRA 10(-9), 10(-8) and 10(-7) M resulted in the inhibition of @entity4 -induced @entity5 phosphorylation. ATRA did not affect the increased expression of integrins a5 and b1 suggesting that this was not the mechanisms of inhibition of @entity5 phosphorylation. ATRA also inhibited the survival of dormant clones in a dose dependent manner and induced a distressed appearance in the remaining cells. CONCLUSIONS: These data suggest that ATRA, which is currently being tested in clinical trials in @entity0 , may have a potential value in the treatment of resistant micrometastases. No significant financial relationships to disclose.

title: All @entity6 modulates survival signaling in dormant XXXX cells.

answer: @entity0


abstract: UNASSIGNED: 654 Background: At the time of diagnosis, early stages of @entity0 already have microscopic @entity1 in the bone marrow. These @entity1 are resistant to adjuvant chemotherapy. The mechanisms of this resistance are not understood. In a model we developed, @entity4 ( @entity4 ), present in large deposits in the bone @entity3 , inhibits proliferation of well-differentiated @entity0 cells and induces a state of dormancy. In turn, @entity4 also induces an increased expression of integrins a5 and b1. Through these integrins, the cells bind @entity8 and activate survival signaling through the PI3 kinase/ @entity5 pathway. Disruption of this signaling may induce cell death in the dormant cells or render them susceptible to cytotoxic therapy. @entity7 , that have reported activity against @entity2 cells, have been shown to modulate @entity5 phosphorylation. METHODS: We investigated the role of all @entity6 (ATRA) in inhibiting @entity5 activation in dormant clones and their survival. Two well-differentiated @entity0 cell lines, MCF-7 and T-47D were used in the studies. Cells were incubated with @entity4 10 ng/ml in @entity8 -coated tissue culture plates at clonogenic densities and ATRA was added at variable concentrations after three days in culture for an additional three or six days. Colonies of 2-10 cells (dormant clones) were counted and lysates were analyzed by Western blot. RESULTS: @entity4 upregulated the expression of integrins a5 and b1 on Western blots after three and six days and increased the phosphorylation of @entity5 and its downstream target @entity9 /beta. Incubation of the dormant cells with ATRA 10(-9), 10(-8) and 10(-7) M resulted in the inhibition of @entity4 -induced @entity5 phosphorylation. ATRA did not affect the increased expression of integrins a5 and b1 suggesting that this was not the mechanisms of inhibition of @entity5 phosphorylation. ATRA also inhibited the survival of dormant clones in a dose dependent manner and induced a distressed appearance in the remaining cells. CONCLUSIONS: These data suggest that ATRA, which is currently being tested in clinical trials in @entity0 , may have a potential value in the treatment of resistant micrometastases. No significant financial relationships to disclose.

title: All XXXX modulates survival signaling in dormant @entity0 cells.

answer: @entity6


abstract: @entity6 (avian paramyxovirus-1) was isolated from pigeons in 12 states between May 1984 and December 1985. One of the isolates was from a feral pigeon; the remainder were from privately owned pigeon lofts. Use of monoclonal antibodies showed seven of the eight isolates tested to be indistinguishable from the 1982 and 1983 Great Britain and European isolates. Clinical signs were @entity4 , torticollis, @entity3 , incoordination, and @entity2 . Pigeons inoculated with the paramyxovirus-1 isolates intravenously or intramuscularly developed clinical disease identical to that described for natural infection; however, only one pigeon inoculated intranasally developed clinical signs. The mean @entity2 time for inoculated pigeons was 9.5 days, with a range of 4 to 25. Virus was shed for up to 20 days. Primary lesions observed on necropsy were gastroenterocolitis and @entity0 . @entity5 experimentally infected by the cloacal, intranasal, or caudal thoracic air-sac route remained healthy. However, the intracerebral pathogenicity index (ICPI) in day-old @entity5 was similar to that observed with velogenic @entity6 isolates. Four of six isolates inoculated intravenously into 6-week-old @entity5 induced @entity1 .

title: Characterization of XXXX (avian paramyxovirus-1) isolated from pigeons.

answer: @entity6


abstract: OBJECTIVES: Normal pressure @entity3 (NPH) is a treatable @entity1 that appears in older adults, lacks specific diagnostic criteria, and resembles symptoms seen in @entity2 ( @entity2 ). Presently, differentiating NPH from @entity2 in the early stages of symptom presentation remains difficult. This study established whether olfactory testing may be useful in this regard. In addition, we determined whether olfactory function of NPH @entity0 differed before and after @entity4 ( @entity4 ), as well as six months after surgical implantation of a ventriculoperitoneal (VP) shunt. @entity0 AND METHODS: Twenty-two NPH @entity0 (mean age=77.6yrs), 14 age- and gender-matched healthy controls (mean age=79.9yrs), and 7 @entity2 @entity0 (mean age=75.5yrs) were administered the 40-item University of Pennsylvania Smell Identification Test (UPSIT). Eighteen of the 22 NPH @entity0 were also tested following @entity4 and 8 @entity0 were tested six months following implantation of VP shunt. RESULTS: Prior to @entity4 , @entity0 with NPH scored significantly higher on the UPSIT than those with @entity2 [respective means (SDs)=26.9 (7.1) _ 14.1 (4.7)]. While the mean NPH score was significantly below that of the matched controls [control mean (SD)=32.7 (6.7)], their test scores were nonetheless within the general normal range, as determined from published normative data (48th percentile). The UPSIT scores did not differ significantly among the three longitudinal time points in the NPH @entity0 . CONCLUSION: Olfactory testing may be useful in differentiating between @entity0 with NPH and @entity0 with @entity2 . Odor identification test scores of NPH @entity0 are not influenced by the release of intracranial pressure via @entity4 or six months following implantation of a VP shunt.

title: Olfactory ability in normal pressure XXXX as compared to @entity2 and healthy controls.

answer: @entity3


abstract: OBJECTIVES: Normal pressure @entity3 (NPH) is a treatable @entity1 that appears in older adults, lacks specific diagnostic criteria, and resembles symptoms seen in @entity2 ( @entity2 ). Presently, differentiating NPH from @entity2 in the early stages of symptom presentation remains difficult. This study established whether olfactory testing may be useful in this regard. In addition, we determined whether olfactory function of NPH @entity0 differed before and after @entity4 ( @entity4 ), as well as six months after surgical implantation of a ventriculoperitoneal (VP) shunt. @entity0 AND METHODS: Twenty-two NPH @entity0 (mean age=77.6yrs), 14 age- and gender-matched healthy controls (mean age=79.9yrs), and 7 @entity2 @entity0 (mean age=75.5yrs) were administered the 40-item University of Pennsylvania Smell Identification Test (UPSIT). Eighteen of the 22 NPH @entity0 were also tested following @entity4 and 8 @entity0 were tested six months following implantation of VP shunt. RESULTS: Prior to @entity4 , @entity0 with NPH scored significantly higher on the UPSIT than those with @entity2 [respective means (SDs)=26.9 (7.1) _ 14.1 (4.7)]. While the mean NPH score was significantly below that of the matched controls [control mean (SD)=32.7 (6.7)], their test scores were nonetheless within the general normal range, as determined from published normative data (48th percentile). The UPSIT scores did not differ significantly among the three longitudinal time points in the NPH @entity0 . CONCLUSION: Olfactory testing may be useful in differentiating between @entity0 with NPH and @entity0 with @entity2 . Odor identification test scores of NPH @entity0 are not influenced by the release of intracranial pressure via @entity4 or six months following implantation of a VP shunt.

title: Olfactory ability in normal pressure @entity3 as compared to XXXX and healthy controls.

answer: @entity2


abstract: BACKGROUND: @entity0 with @entity1 ( @entity1 ) exhibit poor decision-making, and the underlying neural correlates are unclear. We used voxel-based morphometry with Diffeomorphic Anatomical Registration through Exponentiated Lie algebra to examine this issue. METHODS: The decision-making abilities of 20 @entity0 with @entity1 and 37 healthy controls (HCs) were measured with a computerized Iowa Gambling Task (IGT). We assessed the local gray matter volumes of the @entity0 and HCs and their correlations with decision-making performance, disease duration, disease severity, and anti- @entity2 medication dose. RESULTS: Compared with the HCs, the @entity0 with @entity1 exhibited poor IGT performances. The gray matter volumes in the medial orbitofrontal cortex, @entity3 , and right middle frontal gyrus were decreased in the @entity0 . Results in the regression analysis showed that lateral orbitofrontal volume correlated with performance in the IGT in @entity1 . Regions that correlated with disease duration, severity, and medication dose did not overlap with orbitofrontal regions. CONCLUSION: Our results indicate that the lateral and medial orbitofrontal cortex are related to decision-making in @entity1 @entity0 . Since the medial orbitofrontal cortex is shown to be involved in monitoring reward, reward monitoring seems to be impaired as a whole in @entity1 @entity0 . Meanwhile, the lateral region is related to evaluation of punishment, which is considered to have an influence on individual differences in decision-making performance in @entity1 @entity0 .

title: Decision-making performance in XXXX correlates with lateral orbitofrontal volume.

answer: @entity1


abstract: BACKGROUND/OBJECTIVES: Previous studies have reported that @entity0 with @entity3 have @entity1 . Here we developed a simple music-based assay to assess @entity0 's ability to associate a minor chord with sadness. We further characterize correlations between impaired musical responses and @entity2 symptoms. METHOD: We exposed @entity0 sequentially to two sets of sound stimuli, first a @entity4 progression and chord, and second a @entity5 progression and chord. @entity0 were asked which stimulus they associated with sadness, the first set, the second set, or neither. The severity of @entity2 symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). Study @entity0 were 29 @entity0 diagnosed with @entity3 and 29 healthy volunteers matched in age, gender and musical background. RESULT: 37.9% (95% confidence interval [CI]:19.1-56.7) of @entity0 with @entity3 associated the minor chord set as sad, compared with 97.9% (95%CI: 89.5-103.6) of controls. Four @entity0 were diagnosed with treatment-resistant @entity3 , and all four failed to associate the minor chord with sadness. @entity0 who did not recognize minor chords as sad had significantly higher scores on all PANSS subscales. CONCLUSIONS: A simple test allows music-evoked emotions to be assessed in @entity3 @entity0 , and may show potential relationships between music-evoked emotions and @entity2 symptoms.

title: Music-evoked emotions in XXXX .

answer: @entity3


abstract: BACKGROUND AND AIMS: The concern over the weight gain problem continues to grow among both the international scientific community and public health authorities, since overweight and @entity1 prevalence rates continue to increase worldwide. In Chile, two out of three @entity0 are overweight, whereas 25% of the adult population is @entity1 . Abdominal fat, has been linked to the development of a number of @entity2 . Waist circumference (WC) and the waist:height ratio (WHtR) have recently been evidenced as good predictors of metabolic risk for both adults and @entity0 . Thus, the present work aims at establishing smoothed centile charts and @entity3 tables for WC and WHtR for Chilean adults based on data from the National Health Survey-ENS, in order to have reliable information for identifying groups at risk. METHODS AND RESULTS: A sample of 4788 subjects aged 15-75 years old (mean age 46      18 years old) was considered. Body weight, height, and WC were measured and Body Mass Index (BMI) and WHtR were also determined. Percentiles were calculated using the L (curve Box-Cox), M (curve median), S (curve coefficient of variation) method. In the @entity1 group the WC cutoff values were 99.75  cm and 92.35  cm for @entity0 and @entity0 , respectively. The cutoff point for WHtR was 0.59 for both @entity1 @entity0 and @entity0 . CONCLUSION: The study shows, for the first time, reference values for WC and WHtR for Chilean adults.

title: Waist circumference and waist:height ratio percentiles using XXXX method in Chilean population.

answer: @entity3


abstract: BACKGROUND AND AIMS: @entity4 ( @entity4 ) was demonstrated to be  involved in the occurrence and development of @entity1 ( @entity1 ). The goal of the present study was to investigate the relationship between serum @entity4 levels and carotid intima-media thickness ( @entity3 ) in @entity0 with a low-to-moderate @entity1 risk. METHODS AND RESULTS: Subjects with normal kidney function were selected from the Shanghai Obesity Study. Serum @entity4 levels were determined by sandwich enzyme-linked immunosorbent assay. @entity3 was measured by ultrasonography. The Framingham risk score (FRS) was used to assess @entity1 risk. A total of 392 @entity0 with low @entity1 risk and 372 @entity0 with moderate @entity1 risk were enrolled. The recognition rate of an elevated @entity3 was 85.66% with the combination of a moderate @entity1 risk and high serum @entity4 levels, which was greater than that with either parameter alone (65.44% and 61.03%, respectively). Subjects with high serum @entity4 levels, and either low or moderate @entity1 risk, were more likely to have elevated @entity3 than those with low serum @entity4 levels and low @entity1 risk (P  =  0.014 and 0.001, respectively). The serum @entity4 levels were independently and positively associated with @entity3 in subjects with low or moderate @entity1 risk (both P  =  0.007). CONCLUSION: In @entity0 with low-to-moderate @entity1 risk, serum @entity4 levels were associated independently and positively with @entity3 . As a complementary index, serum @entity4 levels strengthen the capacity of the FRS to identify subclinical @entity2 .

title: Contribution of XXXX to Framingham risk score for identifying subclinical @entity2 in Chinese @entity0 .

answer: @entity4


abstract: BACKGROUND AND AIMS: @entity4 ( @entity4 ) was demonstrated to be  involved in the occurrence and development of @entity1 ( @entity1 ). The goal of the present study was to investigate the relationship between serum @entity4 levels and carotid intima-media thickness ( @entity3 ) in @entity0 with a low-to-moderate @entity1 risk. METHODS AND RESULTS: Subjects with normal kidney function were selected from the Shanghai Obesity Study. Serum @entity4 levels were determined by sandwich enzyme-linked immunosorbent assay. @entity3 was measured by ultrasonography. The Framingham risk score (FRS) was used to assess @entity1 risk. A total of 392 @entity0 with low @entity1 risk and 372 @entity0 with moderate @entity1 risk were enrolled. The recognition rate of an elevated @entity3 was 85.66% with the combination of a moderate @entity1 risk and high serum @entity4 levels, which was greater than that with either parameter alone (65.44% and 61.03%, respectively). Subjects with high serum @entity4 levels, and either low or moderate @entity1 risk, were more likely to have elevated @entity3 than those with low serum @entity4 levels and low @entity1 risk (P  =  0.014 and 0.001, respectively). The serum @entity4 levels were independently and positively associated with @entity3 in subjects with low or moderate @entity1 risk (both P  =  0.007). CONCLUSION: In @entity0 with low-to-moderate @entity1 risk, serum @entity4 levels were associated independently and positively with @entity3 . As a complementary index, serum @entity4 levels strengthen the capacity of the FRS to identify subclinical @entity2 .

title: Contribution of @entity4 to Framingham risk score for identifying subclinical XXXX in Chinese @entity0 .

answer: @entity2


abstract: BACKGROUND AND AIMS: @entity4 ( @entity4 ) was demonstrated to be  involved in the occurrence and development of @entity1 ( @entity1 ). The goal of the present study was to investigate the relationship between serum @entity4 levels and carotid intima-media thickness ( @entity3 ) in @entity0 with a low-to-moderate @entity1 risk. METHODS AND RESULTS: Subjects with normal kidney function were selected from the Shanghai Obesity Study. Serum @entity4 levels were determined by sandwich enzyme-linked immunosorbent assay. @entity3 was measured by ultrasonography. The Framingham risk score (FRS) was used to assess @entity1 risk. A total of 392 @entity0 with low @entity1 risk and 372 @entity0 with moderate @entity1 risk were enrolled. The recognition rate of an elevated @entity3 was 85.66% with the combination of a moderate @entity1 risk and high serum @entity4 levels, which was greater than that with either parameter alone (65.44% and 61.03%, respectively). Subjects with high serum @entity4 levels, and either low or moderate @entity1 risk, were more likely to have elevated @entity3 than those with low serum @entity4 levels and low @entity1 risk (P  =  0.014 and 0.001, respectively). The serum @entity4 levels were independently and positively associated with @entity3 in subjects with low or moderate @entity1 risk (both P  =  0.007). CONCLUSION: In @entity0 with low-to-moderate @entity1 risk, serum @entity4 levels were associated independently and positively with @entity3 . As a complementary index, serum @entity4 levels strengthen the capacity of the FRS to identify subclinical @entity2 .

title: Contribution of @entity4 to Framingham risk score for identifying subclinical @entity2 in Chinese XXXX .

answer: @entity0


abstract: BACKGROUND: Early onset @entity7 ( @entity5 ) and @entity6 in childhood pose significant challenges for @entity0 and carers and are the cause of @entity4 . It is particularly tragic when the @entity0 cannot make use of early cochlear implantation (CI) technology to relieve @entity6 and improve language and communication, because severe cervical and truncal @entity7 brushes off the magnetic amplifier behind the ears. Bilateral globus pallidus internus (GPi) deep brain stimulation (DBS) neuromodulation can reduce @entity5 , thus supporting CI neuromodulation success. METHODS: We describe the importance of the order of dual neuromodulation surgery for @entity7 and @entity6 . First with bilateral GPi DBS using a rechargeable ACTIVA-RC neurostimulator followed 5 months later by unilateral CI with a Harmony (BTE) Advanced Bionics Hi Res 90  K cochlear device. This double neuromodulation was performed in series in a 12.5  kg 5 year-old ex-24 week gestation-born twin without a cerebellum. RESULTS: Relief of @entity5 enabled continuous use of the CI amplifier. Language understanding and communication improved. @entity8 abated. Tolerance of sitting increased with emergence of manual function. @entity1 ensued 10 days after ACTIVA-RC removal for @entity2 at 3 years and 10 months. He required intensive care and DBS re-implantation 3 weeks later together with 8 months of hospital care. Today he is virtually back to the level of functioning before the DBS removal in 2012 and background medication continues to be slowly weaned. CONCLUSION: This case illustrates that early neuromodulation with DBS for @entity3 followed by CI for @entity6 is beneficial. Both should be considered early i.e. under the age of five years. The DBS should precede the CI to maximise @entity7 reduction and thus benefits from CI. This requires close working between the paediatric DBS and CI services.

title: Bilateral globus pallidus internus deep brain stimulation for XXXX supports success of cochlear implantation in a 5-year old ex-24  week preterm twin with absent cerebellar hemispheres.

answer: @entity3


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: @entity7 (Burkill) F.H. Chen (Araliaceae) has a long history of clinical application in China for the treatment of @entity1 . @entity7 @entity5 (PNS) have been proven to be the major cardioprotective substances of @entity7 (Burkill) F.H. Chen (Araliaceae). AIM OF THE STUDY: The current study further investigated the molecular mechanisms associated with the cardioprotective effect of PNS. MATERIALS AND METHODS: C57BL/6J @entity0 were subject to @entity4 ( @entity6 )-induced @entity3 in the absence or presence of PNS treatment. Histological, immunohistochemical and molecular biological approaches were taken to assess the effects of PNS treatment on @entity6 -induced @entity3 and ensuing fibrogenesis. RESULTS: PNS treatment significantly attenuated @entity6 -induced @entity3 and @entity2 . The expression of an anti-fibrotic microRNA, @entity8 , was significantly decreased in @entity6 -challenged @entity0 hearts. In contrast, PNS treatment resulted in increased cardiac expression of @entity8 . The expression of @entity8 target genes including Collagen (Col) 1a1, Col1a2, Col3a1 and Col5a1, fibrillin 1 (Fbn1) as well as TGFb1 was significantly increased by @entity6 , which exhibited decreased expression by PNS intervention. CONCLUSIONS: Our results demonstrate for the first time that the cardioprotective effects of PNS could in part implicate increased expression of @entity8 in the heart, which may help increase the understanding of the pharmacological activities of PNS in treating @entity1 .

title: @entity8 is implicated in the cardioprotective activity of @entity7 XXXX against @entity4 -induced myocardial fibrogenesis.

answer: @entity5


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: @entity7 (Burkill) F.H. Chen (Araliaceae) has a long history of clinical application in China for the treatment of @entity1 . @entity7 @entity5 (PNS) have been proven to be the major cardioprotective substances of @entity7 (Burkill) F.H. Chen (Araliaceae). AIM OF THE STUDY: The current study further investigated the molecular mechanisms associated with the cardioprotective effect of PNS. MATERIALS AND METHODS: C57BL/6J @entity0 were subject to @entity4 ( @entity6 )-induced @entity3 in the absence or presence of PNS treatment. Histological, immunohistochemical and molecular biological approaches were taken to assess the effects of PNS treatment on @entity6 -induced @entity3 and ensuing fibrogenesis. RESULTS: PNS treatment significantly attenuated @entity6 -induced @entity3 and @entity2 . The expression of an anti-fibrotic microRNA, @entity8 , was significantly decreased in @entity6 -challenged @entity0 hearts. In contrast, PNS treatment resulted in increased cardiac expression of @entity8 . The expression of @entity8 target genes including Collagen (Col) 1a1, Col1a2, Col3a1 and Col5a1, fibrillin 1 (Fbn1) as well as TGFb1 was significantly increased by @entity6 , which exhibited decreased expression by PNS intervention. CONCLUSIONS: Our results demonstrate for the first time that the cardioprotective effects of PNS could in part implicate increased expression of @entity8 in the heart, which may help increase the understanding of the pharmacological activities of PNS in treating @entity1 .

title: @entity8 is implicated in the cardioprotective activity of XXXX @entity5 against @entity4 -induced myocardial fibrogenesis.

answer: @entity7


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: @entity7 (Burkill) F.H. Chen (Araliaceae) has a long history of clinical application in China for the treatment of @entity1 . @entity7 @entity5 (PNS) have been proven to be the major cardioprotective substances of @entity7 (Burkill) F.H. Chen (Araliaceae). AIM OF THE STUDY: The current study further investigated the molecular mechanisms associated with the cardioprotective effect of PNS. MATERIALS AND METHODS: C57BL/6J @entity0 were subject to @entity4 ( @entity6 )-induced @entity3 in the absence or presence of PNS treatment. Histological, immunohistochemical and molecular biological approaches were taken to assess the effects of PNS treatment on @entity6 -induced @entity3 and ensuing fibrogenesis. RESULTS: PNS treatment significantly attenuated @entity6 -induced @entity3 and @entity2 . The expression of an anti-fibrotic microRNA, @entity8 , was significantly decreased in @entity6 -challenged @entity0 hearts. In contrast, PNS treatment resulted in increased cardiac expression of @entity8 . The expression of @entity8 target genes including Collagen (Col) 1a1, Col1a2, Col3a1 and Col5a1, fibrillin 1 (Fbn1) as well as TGFb1 was significantly increased by @entity6 , which exhibited decreased expression by PNS intervention. CONCLUSIONS: Our results demonstrate for the first time that the cardioprotective effects of PNS could in part implicate increased expression of @entity8 in the heart, which may help increase the understanding of the pharmacological activities of PNS in treating @entity1 .

title: @entity8 is implicated in the cardioprotective activity of @entity7 @entity5 against XXXX -induced myocardial fibrogenesis.

answer: @entity4


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: @entity7 (Burkill) F.H. Chen (Araliaceae) has a long history of clinical application in China for the treatment of @entity1 . @entity7 @entity5 (PNS) have been proven to be the major cardioprotective substances of @entity7 (Burkill) F.H. Chen (Araliaceae). AIM OF THE STUDY: The current study further investigated the molecular mechanisms associated with the cardioprotective effect of PNS. MATERIALS AND METHODS: C57BL/6J @entity0 were subject to @entity4 ( @entity6 )-induced @entity3 in the absence or presence of PNS treatment. Histological, immunohistochemical and molecular biological approaches were taken to assess the effects of PNS treatment on @entity6 -induced @entity3 and ensuing fibrogenesis. RESULTS: PNS treatment significantly attenuated @entity6 -induced @entity3 and @entity2 . The expression of an anti-fibrotic microRNA, @entity8 , was significantly decreased in @entity6 -challenged @entity0 hearts. In contrast, PNS treatment resulted in increased cardiac expression of @entity8 . The expression of @entity8 target genes including Collagen (Col) 1a1, Col1a2, Col3a1 and Col5a1, fibrillin 1 (Fbn1) as well as TGFb1 was significantly increased by @entity6 , which exhibited decreased expression by PNS intervention. CONCLUSIONS: Our results demonstrate for the first time that the cardioprotective effects of PNS could in part implicate increased expression of @entity8 in the heart, which may help increase the understanding of the pharmacological activities of PNS in treating @entity1 .

title: XXXX is implicated in the cardioprotective activity of @entity7 @entity5 against @entity4 -induced myocardial fibrogenesis.

answer: @entity8


abstract: The action of @entity3 ( @entity5 ) on extramural coronary arteries (CA) of @entity1 , @entity4 , and @entity0 was tested in vitro. @entity5 dilated precontracted @entity1 CA in @entity2 on the state of endothelium. This dilation was mediated through muscarinic receptors since @entity6 inhibited it effectively. Preparations without active precontraction were not influenced at all or slightly dilated. Both @entity0 and porcine CA were exclusively contracted by @entity5 independently of the presence or absence of precontraction. The @entity5 contraction in porcine CA was found to be endothelium-independent, but also inhibited by @entity6 as well as the @entity5 contraction in @entity0 CA. Adrenoceptor blockers did not influence @entity5 reactivity. High concentrations of @entity5 (greater than 10(-5) mol/l) decreased the further responsiveness of the vessels to the mediator (tested in @entity1 and @entity4 only). Spontaneous mechanical activity was registered only in @entity0 CA. Different @entity5 reactivity in @entity1 compared with @entity4 and @entity0 is interpreted as species-dependent. It must be taken into account when @entity0 coronary physiology is modeled in animals.

title: The action of XXXX on isolated coronary arteries of different species.

answer: @entity3


abstract: Described are 26 cases of @entity1 . Of these cysts, 54% were in the sylvian cistern, three (1.2%) were in the suprasellar cistern, and the rest were over the cerebral sulci. There were symptoms of @entity4 at presentation in 30.8%, and in 23% there were symptoms of @entity6 and compression of the brain. A total of 61.5% presented with @entity5 and/or @entity3 . @entity0 and @entity2 accounted for 35% of these cysts. Associated @entity8 were present in five cases. There was a male preponderance. Left-sided lesions accounted for 61.5% of the lesions. The radiologic appearances, especially of @entity7 , and the differential diagnoses of these lesions are discussed. Their recognition and the role of surgery are stressed.

title: XXXX : computed tomography findings.

answer: @entity1


abstract: @entity10 (CAE), an orally absorbed prodrug of @entity7 , was evaluated for its efficacy and safety in the treatment of @entity5 ( @entity8 , @entity9 , @entity4 and @entity6 ) in general practice in the United Kingdom. A total of 385 @entity0 aged 14 or over were enrolled in a randomized study to compare @entity10 250 mg b.d. for 5 days with @entity1 / @entity3 ( @entity11 , AUG) 375 mg t.d.s. for 5 days. Of 175 clinically assessable @entity0 treated with @entity10 , 136 were cured and 33 improved (97% success rate). Of 188 assessable @entity0 given @entity11 , 155 were cured and 29 improved (98% success rate). Sixty-four @entity0 treated with @entity10 were evaluable for bacteriological response: 47 (73%) of the causative pathogens were eradicated, as compared with 62 of 86 (72%) in @entity0 treated with @entity11 . Thirteen out of 181 (7%) @entity0 treated with @entity10 experienced drug-related adverse events, including 4% with @entity2 . In the @entity11 group 24 out of 204 (12%) @entity0 had a drug-related adverse event, including 5% with @entity2 . In conclusion, @entity10 at a dose of 250 mg b.d. appears to be as safe and effective as @entity11 at the higher dose of 375 mg t.d.s. in the treatment of @entity5 .

title: A comparison of the efficacy and safety of XXXX and @entity11 in the treatment of @entity5 .

answer: @entity10


abstract: @entity10 (CAE), an orally absorbed prodrug of @entity7 , was evaluated for its efficacy and safety in the treatment of @entity5 ( @entity8 , @entity9 , @entity4 and @entity6 ) in general practice in the United Kingdom. A total of 385 @entity0 aged 14 or over were enrolled in a randomized study to compare @entity10 250 mg b.d. for 5 days with @entity1 / @entity3 ( @entity11 , AUG) 375 mg t.d.s. for 5 days. Of 175 clinically assessable @entity0 treated with @entity10 , 136 were cured and 33 improved (97% success rate). Of 188 assessable @entity0 given @entity11 , 155 were cured and 29 improved (98% success rate). Sixty-four @entity0 treated with @entity10 were evaluable for bacteriological response: 47 (73%) of the causative pathogens were eradicated, as compared with 62 of 86 (72%) in @entity0 treated with @entity11 . Thirteen out of 181 (7%) @entity0 treated with @entity10 experienced drug-related adverse events, including 4% with @entity2 . In the @entity11 group 24 out of 204 (12%) @entity0 had a drug-related adverse event, including 5% with @entity2 . In conclusion, @entity10 at a dose of 250 mg b.d. appears to be as safe and effective as @entity11 at the higher dose of 375 mg t.d.s. in the treatment of @entity5 .

title: A comparison of the efficacy and safety of @entity10 and @entity11 in the treatment of XXXX .

answer: @entity5


abstract: @entity10 (CAE), an orally absorbed prodrug of @entity7 , was evaluated for its efficacy and safety in the treatment of @entity5 ( @entity8 , @entity9 , @entity4 and @entity6 ) in general practice in the United Kingdom. A total of 385 @entity0 aged 14 or over were enrolled in a randomized study to compare @entity10 250 mg b.d. for 5 days with @entity1 / @entity3 ( @entity11 , AUG) 375 mg t.d.s. for 5 days. Of 175 clinically assessable @entity0 treated with @entity10 , 136 were cured and 33 improved (97% success rate). Of 188 assessable @entity0 given @entity11 , 155 were cured and 29 improved (98% success rate). Sixty-four @entity0 treated with @entity10 were evaluable for bacteriological response: 47 (73%) of the causative pathogens were eradicated, as compared with 62 of 86 (72%) in @entity0 treated with @entity11 . Thirteen out of 181 (7%) @entity0 treated with @entity10 experienced drug-related adverse events, including 4% with @entity2 . In the @entity11 group 24 out of 204 (12%) @entity0 had a drug-related adverse event, including 5% with @entity2 . In conclusion, @entity10 at a dose of 250 mg b.d. appears to be as safe and effective as @entity11 at the higher dose of 375 mg t.d.s. in the treatment of @entity5 .

title: A comparison of the efficacy and safety of @entity10 and XXXX in the treatment of @entity5 .

answer: @entity11


abstract: BACKGROUND: Even with great advances in surgery and improved clinical outcome, morbidity and mortality are still high for large volume @entity7 ( @entity7 ). Recently, gamma knife radiosurgery (GKS) has proven to be a safe and effective treatment for many @entity0 with intracranial @entity7 . However, single session GKS may increase the risk of radiation-induced @entity3 for large @entity7 . Recently, fractionated gamma knife radiosurgery (FGKS) has been performed for an increasing number of @entity0 with surgically high-risk and large @entity2 . In this study, we report our results on the efficacy and safety of FGKS for large @entity7 . METHODS: The authors performed a retrospective review of 70 @entity0 who underwent GKS for large volume (>10 cm(3)) intracranial @entity7 between 2004 and 2015, with a minimum follow-up of 12 months. The authors classified these @entity0 into two groups of single-session GKS, fractionated GKS (FGKS). The @entity0 were followed by clinical examination as well as serial imaging with magnetic resonance imaging (MRI). RESULTS: In the single-session GKS group (42 @entity0 ), the median @entity2 volume was 15.2 cm(3) (range 10.3-48.3 cm(3)); the median prescription dose was 12 Gy (range 8-14 Gy), and the median follow-up duration was 57.8 months (range 14.5-128.4 months). In the FGKS group (28 @entity0 ), the median @entity2 volume was 21 cm(3) (range 10.2-54.7 cm(3)), and the median prescription was 7.5 Gy in 2 fractions (range 5-8 Gy), 6 Gy in 3 fractions (range 5-6.5 Gy), 4.5 Gy in 4 fractions. The median follow-up duration for the FGKS group was 50 months (range 12.5-90.6 months). The overall 5-year @entity2 control rate was 92.9% in the FGKS group and 88.1% in the single-session GKS group. Fourteen (33.3%) symptomatic complications after single session GKS were noted, including 5 cases of @entity5 , 4 of @entity4 , 3 of peritumoral @entity1 , and 2 of @entity6 . Two (7.1%) symptomatic complications after FGKS were noted, including 2 cases of @entity5 . The FGKS group had higher progression free survival (PFS) rate at 5 years (92.9% vs. 88.1%), but the differences did not reach statistical significance (p=0.389). The @entity0 in the FGKS group, however, experienced a lower complication rate compared with @entity0 with single session GKS group (p=0.017, hazard ratio, 5.7: 1). CONCLUSION: When the large-volume (>10 cm(3)) intracranial @entity7 are expected to have high morbidity after microsurgery and for @entity0 that have a poor medical status for surgery, FGKS can be considered a good alternative with @entity2 control and lower complications rates compared with single-session GKS (p=0.017).

title: Is fractionated Gamma Knife radiosurgery a safe and effective treatment approach for large volume (>10 cm(3)) XXXX ?

answer: @entity7


abstract: BACKGROUND: Studies have demonstrated certain hemodynamic characteristics featuring the @entity1 status of @entity2 using computational fluid dynamics. These studies were conducted based on the comparison of a large number of ruptured and @entity3 . However, not only @entity3 size and location but also perianeurysm environment, such as @entity5 and intracranial pressure, affect hemodynamic changes. We hypothesized that a case in which ruptured and unruptured @entity2 simultaneously exist in the same location would be an ideal model to demonstrate hemodynamic characteristics of the @entity1 status. CASE DESCRIPTION: We report 2 rare cases with @entity4 , each of which involved 2 @entity3 at the common parent artery. One @entity0 had 2 anterior communicating @entity2 , and the other @entity0 had 2 middle cerebral @entity2 . Preoperative morphologic and hemodynamic examinations were performed to diagnose the @entity1 status of the 2 @entity3 , and each ruptured @entity3 was then confirmed during surgical clipping. Morphologic evaluation revealed higher shape indexes in both @entity6 . Lower wall shear stress, wall shear stress gradient, and @entity3 formation indicator were observed in both @entity6 . In contrast, @entity6 had a higher oscillatory shear index and oscillatory velocity index, which was the novel hemodynamic parameter to quantify the fluctuation of flow velocity vector. CONCLUSIONS: Quantitative characterization of the hemodynamic environment can distinguish the @entity1 status by using appropriate models minimizing certain bias caused by @entity4 and @entity3 location.

title: Hemodynamic Differences Between Ruptured and Unruptured XXXX Simultaneously Existing in the Same Location: 2 Case Reports and Proposal of a Novel Parameter Oscillatory Velocity Index.

answer: @entity2


abstract: BACKGROUND: Post endovascular @entity1 repair (EVAR) @entity2 and the need for reintervention are challenging. Additional endovascular treatment is advised for Type Ia @entity2 detected on post-EVAR completion angiogram. This study analyzes management and late outcome of these @entity2 . @entity0 POPULATION AND METHODS: This is a retrospective review of prospectively collected date of EVAR @entity0 during a 10-year period. All post-EVAR Type Ia @entity2 on completion angiogram were identified (Group A) and their early (30-day) and late outcomes were compared to @entity0 without @entity2 (Group B). A Kaplan-Meier analysis was used for survival analysis, sac expansion, late Type Ia endoleak, and reintervention. RESULTS: 71/565 (12.6%) @entity0 had immediate post-EVAR Type Ia endoleak. Early intervention (proximal aortic cuffs and/or stenting) was used in 56/71 (79%) in Group A versus 31/494 (6%) in Group B (p<0.0001). Late Type Ia endoleak was noted in nine @entity0 (13%) in Group A at a mean follow-up of 28 months versus 10 @entity0 (2%) in Group B at a mean follow-up of 32 months (p<0.0001). Late sac expansion and reintervention rates were: 9% and 10% for Group A versus 5% and 3% for Group B (p=0.2698 and p-0.0198), respectively. Freedom rates from late Type Ia @entity2 at 1, 3, and 5 years for Group A were 88%, 85%, and 80% versus 98%, 98%, and 96% for Group B (p<0.001); and for late intervention, 94%, 92%, and 77% for Group A, and 99%, 97%, and 95% for Group B (p=0.007), respectively. Survival rates were similar. CONCLUSIONS: Immediate post-EVAR Type Ia @entity2 are associated with higher rates of early interventions and late @entity2 and re-intervention, which will necessitate strict post-EVAR surveillance.

title: Management of Immediate Post-Endovascular XXXX Repair Type Ia Endoleaks and Late Outcomes.

answer: @entity1


abstract: Weanling gilts were fed either a 12% or 16% protein diet for 10 weeks. Animals fed the 12% protein diet had reduced body weights and @entity1 as measured in the distal radial growth plate. There was no difference in the growth plate widths between the two animal groups, but there was a significant reduction in the daily rate of cell production in the proliferative zone of animals fed the 12% protein diet. No effect of diet on the rate of expansion of the epiphysis at the articular-epiphyseal junction of the distal femur or humerus could be detected. All animals in both groups had morphologic cartilage lesions consistent with early changes associated with @entity2 ( @entity2 ), and there was no difference in the lesion morphology between the dietary groups. Areas of disorderly endochondral ossification in the radial growth plate were associated with perpendicular growth cartilage infractions. Growth plate lesions were characterized by increased widths of the maturing cartilage zone without increased width of the proliferative zone or an increase in the daily rate of cell production. Focal growth plate lesions developed because of a transitory inhibition of cartilage mineralization and resorption. Disorderly foci of endochondral ossification beneath articular cartilage were characterized by an area of chondrocyte @entity0 which prevented normal cartilage matrix mineralization. Lamellae of cartilage @entity0 were also present within the reserve zone of the articular cartilage. These were associated with abnormalities of the cartilage canal vessels, and chondrocyte @entity0 was considered to precede degenerative changes in articular cartilage matrix.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effect of diet on longitudinal bone growth and XXXX in swine.

answer: @entity2


abstract: PURPOSE: To determine whether some of the most often used @entity2 cell lines resemble their original @entity1 . METHODS: Analysis of the literature, @entity0 charts, histopathology, mutations, chromosome status, HLA type, and expression of melanocyte markers on cell lines and their @entity1 . We examined five cell lines and the @entity1 from which they were derived. RESULTS: Four of the five examined @entity1 were unusual: one occupied the orbit, two were recurrences after prior irradiation, and one developed in an eye with a @entity5 . One cell line did not contain the @entity3 mutation, but it was present in the @entity1 . Three of the @entity1 had monosomy 3 (two of these lacked @entity4 expression); however, all five cell lines showed disomy 3 and @entity4 expression. All of the cell lines had gain of 8q. Two cell lines lacked expression of melanocyte markers, although these were present in the corresponding @entity1 . CONCLUSIONS: All cell lines could be traced back to their original @entity2 . Four of the five @entity1 were unusual. Cell lines often differed from their @entity1 in chromosome status and melanocyte markers. However, their specific chromosome aberrations and capacity to continue proliferation characterize them as @entity2 cell lines.

title: XXXX Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

answer: @entity2


abstract: Motor fluctuations and non-response to carbidopa-levodopa (Sinemet) therapy are major problems in the long-term management of @entity1 . Levodopa manipulation, addition of adjuvants, and drug holidays are often unsuccessful. Others have shown that the clinical state of stabilized Parkinsonians can be reversed with intravenous administration of large neutral @entity3 . Reasoning that dietary protein might precipitate motor oscillations and non-response, a low-protein daytime diet (7 g) was offered to fifteen @entity0 . Eighty-six percent of this sample demonstrated immediate sensitivity to Sinemet. While on a low-protein diet, @entity0 ' clinical function was predominantly choreatic. Eight @entity0 required a 10-60 percent reduction in their daily levodopa dose in order to minimize this choreatic tendency. Discontinuation of adjuvants did not compromise motor independence. Conversely, while on a high-protein diet (160 g), @entity0 were predominantly immobile with markedly elevated plasma @entity2 and levodopa levels. Consequently, elimination of dietary protein from breakfast and lunch can offer an effective and easily modified method for the amelioration of motor fluctuations and non-response to Sinemet in @entity1 during working hours.

title: Dietary method for reducing fluctuations in XXXX .

answer: @entity1


abstract: UNASSIGNED: Background: @entity0 with @entity1 frequently have gait deficits that lead to diminished activities of daily living. Identification of motoneuron activity patterns may elucidate new insight into @entity6 and underlying neural systems. The aim of the present study was to investigate @entity3 , identified by motor modules and their activation profiles, in @entity0 with @entity1 (PwMS) during walking compared to those of @entity4 ( @entity4 ), as well as, exploring relationship of @entity3 with walking ability of PwMS. Methods: Seventeen PwMS walked at their natural speed while 12 @entity4 walked at slower than their natural speeds in order to provide normative gait values at matched speeds (spatio-temporal, kinematic, and kinetic parameters and electromyography signals). Non-negative matrix factorization was used to identify @entity3 from eight muscles. Pearson's correlation coefficient was used to evaluate the similarity of motor modules between PwMS and @entity4 . To assess differences in module activations, each module's activation timing was integrated over 100% of gait cycle and the activation percentage was computed in six phases. Results: Fifty-nine% of PwMS and 58% of @entity4 had 4 modules while the remaining of both populations had 3 modules. Module 2 (related to soleus, medial, and lateral gastrocnemius primarily involved in mid and terminal stance) and Module 3 (related to tibialis anterior and rectus femoris primarily involved in early stance, and early and late swing) were comparable across all subjects regardless of synergies number. PwMS had shorter stride length, longer double support phase and push off deficit with respect to @entity4 (p < 0.05). The alterations of activation timing profiles of specific modules in PwMS were associated with their walking deficits (e.g., the reduction of Module 2 activation percentage index in terminal stance, PwMS 35.55    13.23 vs. @entity4 50.51    9.13% p < 0.05, and the push off deficit, PwMS 0.181    0.136 vs. @entity4 0.291    0.062 w/kg p < 0.05). Conclusion: During gait PwMS have synergies numbers similar to healthy @entity0 . Their neurological deficit alters modular control through modifications of the timing activation profiles rather than module composition. These changes were associated with their main @entity2 , @entity5 , and prolonged double support.

title: Are Modular Activations Altered in Lower Limb Muscles of @entity0 with XXXX during Walking? Evidence from Muscle Synergies and Biomechanical Analysis.

answer: @entity1


abstract: UNASSIGNED: Background: @entity0 with @entity1 frequently have gait deficits that lead to diminished activities of daily living. Identification of motoneuron activity patterns may elucidate new insight into @entity6 and underlying neural systems. The aim of the present study was to investigate @entity3 , identified by motor modules and their activation profiles, in @entity0 with @entity1 (PwMS) during walking compared to those of @entity4 ( @entity4 ), as well as, exploring relationship of @entity3 with walking ability of PwMS. Methods: Seventeen PwMS walked at their natural speed while 12 @entity4 walked at slower than their natural speeds in order to provide normative gait values at matched speeds (spatio-temporal, kinematic, and kinetic parameters and electromyography signals). Non-negative matrix factorization was used to identify @entity3 from eight muscles. Pearson's correlation coefficient was used to evaluate the similarity of motor modules between PwMS and @entity4 . To assess differences in module activations, each module's activation timing was integrated over 100% of gait cycle and the activation percentage was computed in six phases. Results: Fifty-nine% of PwMS and 58% of @entity4 had 4 modules while the remaining of both populations had 3 modules. Module 2 (related to soleus, medial, and lateral gastrocnemius primarily involved in mid and terminal stance) and Module 3 (related to tibialis anterior and rectus femoris primarily involved in early stance, and early and late swing) were comparable across all subjects regardless of synergies number. PwMS had shorter stride length, longer double support phase and push off deficit with respect to @entity4 (p < 0.05). The alterations of activation timing profiles of specific modules in PwMS were associated with their walking deficits (e.g., the reduction of Module 2 activation percentage index in terminal stance, PwMS 35.55    13.23 vs. @entity4 50.51    9.13% p < 0.05, and the push off deficit, PwMS 0.181    0.136 vs. @entity4 0.291    0.062 w/kg p < 0.05). Conclusion: During gait PwMS have synergies numbers similar to healthy @entity0 . Their neurological deficit alters modular control through modifications of the timing activation profiles rather than module composition. These changes were associated with their main @entity2 , @entity5 , and prolonged double support.

title: Are Modular Activations Altered in Lower Limb Muscles of XXXX with @entity1 during Walking? Evidence from Muscle Synergies and Biomechanical Analysis.

answer: @entity0


abstract: OBJECTIVE: Previous studies report reduced interoceptive @entity2 ( @entity2 ) using various methods. Recent research suggests that different levels of interoceptive processes aiming at different subdomains of interoceptive abilities must be further distinguished as these levels can be differentially affected. Two important levels refer to interoceptive accuracy (IA) derived from objective performance tasks such as the heartbeat detection task and interoceptive sensibility (IS) as assessed by self-report. There is a lack of studies investigating both IA and IS in @entity2 and examining them in the time course of therapy. The aim of this pilot study was to evaluate the different interoceptive processes - especially IA and IS - in the time course of therapy. METHODS: Fifteen @entity0 with @entity2 (restricting type) from the Psychosomatic Clinic in Windach were investigated three times (T1, T2, T3) during a standardized cognitive-behavioral therapy and compared with 15 matched healthy controls assessed at Ulm University in a comparable design. All @entity0 performed the heartbeat detection task examining IA and completed standard psychological assessments including an assessment of IS. RESULTS: @entity0 with @entity2 showed a significantly decreased weight, higher levels of @entity1 , and both reduced IA and IS compared to healthy controls at T1. Following therapy, @entity0 recovered in terms of weight and @entity1 symptomatology. A descriptive trend for recovering from IA and IS was observed. DISCUSSION: Our findings suggest that interoceptive deficits are present in recovered @entity0 . Therefore, further investigations are needed with more @entity0 , differentiating between relapsed and recovered @entity0 , and more specific training methods to improve interoceptive processes.

title: Interoceptive XXXX in the Time Course of Cognitive-Behavioral Therapy: A Pilot Study.

answer: @entity2


abstract: BACKGROUND: Altered emotional processing, including reduced emotion facial expression and defective emotion recognition, has been reported in @entity0 with @entity2 ( @entity2 ). However, few studies have objectively investigated facial expression abnormalities in @entity2 using neurophysiological techniques. It is not known whether altered facial expression and recognition in @entity2 are related. OBJECTIVE: To investigate possible deficits in facial emotion expression and emotion recognition and their relationship, if any, in @entity0 with @entity2 . METHODS: Eighteen @entity0 with @entity2 and 16 healthy controls were enrolled in this study. Facial expressions of emotion were recorded using a 3D optoelectronic system and analyzed using the facial action coding system. Possible deficits in emotion recognition were assessed using the Ekman test. @entity0 were assessed in one experimental session. Possible relationship between the kinematic variables of facial emotion expression, the Ekman test scores, and clinical and demographic data in @entity0 were evaluated using the Spearman's test and multiple regression analysis. RESULTS: The facial expression of all six basic emotions had slower velocity and lower amplitude in @entity0 in comparison to healthy controls (all Ps   <   0.05). @entity0 also yielded worse Ekman global score and disgust, sadness, and fear sub-scores than healthy controls (all Ps   <   0.001). Altered facial expression kinematics and emotion @entity1 were unrelated in @entity0 (all Ps   >   0.05). Finally, no relationship emerged between kinematic variables of facial emotion expression, the Ekman test scores, and clinical and demographic data in @entity0 (all Ps   >   0.05). CONCLUSION: The results in this study provide further evidence of altered emotional processing in @entity2 . The lack of any correlation between altered facial emotion expression kinematics and emotion @entity1 in @entity0 suggests that these abnormalities are mediated by separate pathophysiological mechanisms.

title: Altered Kinematics of Facial Emotion Expression and Emotion Recognition Deficits Are Unrelated in XXXX .

answer: @entity2


abstract: UNASSIGNED: Breeding @entity1 relies on a phenotypic recurrent selection that takes advantage of the vegetative propagation of this crop. Successive stages of selection (single row trial-SRT; preliminary yield trial-PYT; advanced yield trial-AYT; and uniform yield trials UYT), gradually reduce the number of genotypes as the plot size, number of replications and locations increase. An important feature of this scheme is that, because of the clonal, reproduction of @entity1 , the same identical genotypes are evaluated throughout these four successive stages of selection. For this study data, from 14 years (more than 30,000 data points) of evaluation in a sub-humid tropical environment was consolidated for a meta-analysis. Correlation coefficients for fresh root yield (FRY), dry matter content (DMC), @entity0 ( @entity0 ), and plant type score (PTS) along the different stages of selection were estimated. DMC and PTS measured in different trials showed the highest correlation coefficients, indicating a relatively good repeatability. @entity0 had an intermediate repeatability, whereas FRY had the lowest value. The association between @entity0 and FRY was lower than expected, suggesting that @entity0 in early stages was not reliable as indirect selection for FRY in later stages. There was a consistent decrease in the average performance of clones grown in PYTs compared with the earlier evaluation of the same genotypes at SRTs. A feasible explanation for this trend is the impact of the environment on the physiological and nutritional status of the planting material and/or epigenetic effects. The usefulness of @entity0 is questioned. Measuring this variable takes considerable efforts at harvest time. DMC and FRY showed a weak positive association in SRT (r = 0.21) but a clearly negative one at UYT (r = -0.42). The change in the relationship between these variables is the result of selection. In later stages of selection, the plant is forced to maximize productivity on a dry weight basis either by maximizing FRY or DMC, but not both. Alternatively, the plant may achieve high dry root yield by simultaneously attaining "acceptable" (but not maximum) levels of FRY and DMC.

title: XXXX Breeding II: Phenotypic Correlations through the Different Stages of Selection.

answer: @entity1


abstract: UNASSIGNED: Drought stress is a major abiotic stress threatening plant and crop productivity. In case of fleshy fruits, understanding mechanisms governing water and @entity3 accumulations and identifying genes, QTLs and phenotypes, that will enable trade-offs between fruit growth and quality under @entity0 ( @entity0 ) condition is a crucial challenge for breeders and growers. In the present work, 117 recombinant inbred lines of a population of @entity4 were phenotyped under control and @entity0 conditions. Plant water status, fruit growth and composition were measured and data were used to calibrate a process-based model describing water and @entity3 fluxes in a growing fruit as a function of plant and environment. Eight genotype-dependent model parameters were estimated using a multiobjective evolutionary algorithm in order to minimize the prediction errors of fruit dry and fresh mass throughout fruit development. @entity0 increased the fruit dry matter content (up to 85%) and decreased its fresh weight (up to 60%), big fruit size genotypes being the most sensitive. The mean normalized root mean squared errors of the predictions ranged between 16-18% in the population. Variability in model genotypic parameters allowed us to explore diverse genetic strategies in response to @entity0 . An interesting group of genotypes could be discriminated in which (i) the low loss of fresh mass under @entity0 was associated with high active uptake of @entity5 and low value of the maximum cell wall extensibility, and (ii) the high dry matter content in control treatment (C) was associated with a slow decrease of mass flow. Using 501 SNP markers genotyped across the genome, a QTL analysis of model parameters allowed to detect three main QTLs related to xylem and phloem conductivities, on chromosomes 2, 4, and 8. The model was then applied to design ideotypes with high dry matter content in C condition and low fresh @entity2 in @entity1 . The ideotypes outperformed the RILs especially for large and medium fruit-size genotypes, by combining high pedicel conductance and high active uptake of @entity5 . Interestingly, five small fruit-size RILs were close to the selected ideotypes, and likely bear interesting traits and alleles for adaptation to @entity0 .

title: Model-Assisted Estimation of the Genetic Variability in Physiological Parameters Related to XXXX Fruit Growth under Contrasted Water Conditions.

answer: @entity4


abstract: BACKGROUND: Asthma is a common disease of the airways with a significant burden for the society and for @entity0 ' quality of life. The Social Impact of Respiratory Integrated Outcomes (SIRIO) study estimated a mean cost of 1,177.40     per @entity0 /year in Italy, in 2007. The aim of the present study was to update the cost of persistent @entity1 @entity0 in Italy. METHODS: An observational, retrospective, bottom-up analysis was carried out starting from the data base operating in the Lung Unit of the Specialist Medical Centre (CEMS), Verona (Italy), over the period June 2013-December 2015. @entity0 ' data were recorded over the 12        2  months before the enrollment and during 12        2  months of follow-up. The prospective was the Italian National Health Service and the broad Italian society. Clinical data were measured in terms of forced expiratory volume in 1  s (FEV1%) and number of relapses. Healthcare resources (namely; number of hospitalizations and/or ER admissions; number of visits; drug use and duration, and indirect costs) were recorded. RESULTS: The cohort consisted of 817 @entity0 with persistent @entity1 of different severity. They had a 42.96% male prevalence; a mean (  SE) age of 49.06 (  0.64) years; a mean 87.47% (  0.81) FEV1% pred. in baseline, and 69.16% of subjects had comorbidities. The mean (  SE) number of relapses was 0.91 (  0.09) per @entity0 /year before the enrolment. After 12  months, FEV1% significantly improved by +6.31% (  0.45) from the corresponding baseline value (p    <   0.001). The number of relapses decreased of -0.46 (  0.09) (p    <   0.001). The estimated total annual cost per @entity2 @entity0 was 1,183.14     (  65.79    ) during the 12  months before the enrolment, and 1,290.89     (  68.74    ) throughout the follow-up. The increase was mostly due to the significantly increased duration of therapeutic strategies. The costs of hospitalization, general practitioner and rescue medications were significantly decreased. CONCLUSIONS: The periodic update of cost analysis is a key to monitor the trend of main @entity1 outcomes and related expenditure over time. It allows to plan the most convenient actions in terms of prevention strategies and effective interventions, with the aim of optimizing the healthcare resources consumption and maximizing the impact on clinical outcomes and @entity0 ' quality of life. The role of an appropriate pharmacological strategy still proves crucial in minimizing @entity1 morbidity and the corresponding socio-economic impact.

title: Cost of persistent XXXX in Italy.

answer: @entity1


abstract: The macromolecular permeability of renal capillaries and the intravascular red cell aggregation resulting from 45 min of warm ischaemia were investigated. The effects of the @entity3 oxidase inhibitor @entity1 on these factors and also on the post-ischaemic nephron function were also studied. Following ischaemia there was a more than 10-fold increase in the transport from plasma to renal hilar lymph both of plasma proteins and of two isomers of @entity2 dehydrogenase (LDH)-the nearly neutral LDH-M4 and the negatively charged LDH-H4. The ischaemia also resulted in massive intravascular red cell aggregation, especially in the renal medulla. Through reduction of plasma @entity3 oxidase activity from 13.1 +/- 1.1 microU microliter-1 (mean +/- SEM) to essentially zero by @entity1 , the capillary leakiness was substantially diminished with almost complete normalization after 120 min. At the same time the relative volume of trapped red cells was reduced; in the inner stripe of the outer medulla, for example, it decreased from 11.3 +/- 1.7% in untreated animals to 4.0 +/- 1.1% after treatment with 20 mg of @entity1 given intravenously 3 h before the ischaemia. Oral feeding with 4 mg of @entity1 day-1 for one week gave essentially the same result. The net driving force for filtration after treatment with this drug was thus 19 mmHg, as against 26 mmHg in the normal kidney and the resulting SNGFR was half the normal. The total filtration rate was proportionally more reduced to less than 1/3 of the normal. @entity4 was still present but was not as severe as in untreated kidneys (Karlberg et al., 1982b) where the tubular fluid flow and thereby the filtration are essentially zero. It is suggested that @entity0 free radicals increased the macromolecular permeability and the adhesiveness of white blood cells and that these two factors combined underlie the aggregation of red blood cells in the medullary vasa recta with consequent persistence of medullary ischaemia.

title: Renal capillary permeability and intravascular red cell aggregation after ischaemia. I. Effects of XXXX oxidase activity.

answer: @entity3


abstract: AIMS: To determine occupational association with @entity1 among auto technicians and school teachers. METHODS: One hundred and sixty six subjects were selected for this study. Clinical data was obtained while laboratory investigations including plasma @entity2 and lipid profile were performed. Statistical analysis was done with SPSS 20.0. P<0.05 was taken as statistically significant. RESULTS: School teachers had significantly higher mean total @entity0 and LDL- @entity0 compared to auto technicians. Mean serum @entity3 was significantly higher among auto-technicians compared to school teachers in this study. The prevalence of some conventional cardiovascular risk factors was significantly higher among auto-technicians compared to school teachers: Impaired blood @entity2 (9.6% vs. 1.2%, p<0.05), hypertriglyceridaemia (18.1% vs. 7.2%, p<0.05) and low HDL- @entity0 (47.0% vs. 37.3%, p<0.05) respectively. However elevated LDL- @entity0 (56.6% vs. 32.5%, p<0.05) was significantly more common among school teachers compared to auto-technicians. Based on the WHO and the Harmonized criteria, @entity1 was more frequent among auto-technicians compared to school teachers. (8.4% vs. 1.2% and 19.3% vs. 7.2% respectively, p<0.05) CONCLUSION: The prevalence of @entity1 appears to be significantly higher among auto technicians despite their high level of physical activity, exertion and education compared to teachers. This may be related to the increased occupational exposure to organic and inorganic materials from dust particles, oil and oil related matter and particulate matter among auto technicians. Prompt definitive evaluation of this concept and appropriate health education to encourage safety mechanism can reduce this burden of @entity1 among auto technicians in Nigeria.

title: XXXX and occupation: Any association? Prevalence among auto technicians and school teachers in South West Nigeria.

answer: @entity1